New publication: neoIM, a predictive model for neoantigen immunogenicity

neoIM is the first-in-class immunogenicity predictor with high accuracy in identifying which neoantigens are capable of eliciting a T-cell response. Unlike traditional tools that focus mainly on MHC binding, neoIM directly models immunogenicity and significantly outperforms existing approaches in benchmark datasets and experimental validation.

Key results:

• Demonstrates potential as biomarker, with higher neoIM scores correlating with improved survival in melanoma patients treated with checkpoint inhibitors
• Enables identification of up to 50% more clinically actionable neoantigens for vaccine design
• Achieves up to 30% higher precision than existing predictors in ELISpot assays

The study is now published in Vaccines MDPI.

neoIM is protected under patent EP4229640.

Congratulations to all co-authors: Lena Pfitzer, Gitta Boons, Lien Lybaert, Wim Van Criekinge, Cedric Bogaert, Bruno Fant